JB Pharma continues its outstanding growth path by registering impressive numbers for the Financial Year 2021-22 and the Q1 of the current Financial Year with a growth rate more than 25%, outperforming the market rate of 18% (IQVIA, MAT Jun’22).

With operating revenues at Rs. 2424 Crores and EBITDA at a strong Rs 550 Crores, JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23, ranked at No. 23.

Speaking on the performance of the Company, Nikhil Chopra, CEO and Whole Time Director, JB Pharma said, “Our growth has been nothing less than outstanding for the year 2021-22, being ranked in the top 23 pharmaceutical companies in India. We plan on moving quickly up to No. 20, outperforming all market expectations, with strong showing in our domestic business, especially in the core therapy areas.”

In 2007, JB Pharma became the leading brand in cardiology and nephrology, and in the year 2021 came the market beating ranking at No. 28 in the Indian Pharmaceutical companies with 5 brands featuring in the top 300 brands within the country. It was also in 2021 that new therapeutic categories like Diabetes, Nephrology, Respiratory and Virology were also introduced. Acquisition of Azmarda and Sporlac brands was the other major landmark in the first half of 2022.

“Our domestic business has shown significant momentum with the launch of our new Go-to-Market model which has helped us increase productivity bringing greater focus to domestic business. Our entry into the fast-growing chronic segments like heart failure, diabetes and nephrology, along with the launch of 15 new products in the year has helped push up our share of domestic sales in new products by more than 5%. We will continue to consolidate our new acquisitions with the current portfolio and geographical strengths of JB Pharma, towards consistently delivering market beating growth,” Chopra further added.